(3-chloro-1H-indazol-5-yl)-[6-(1,2,3,6-tetrahydropyridin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-amine | 876343-27-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡唑类
• 英文名称: (3-chloro-1H-indazol-5-yl)-[6-(1,2,3,6-tetrahydropyridin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-amine
• 英文别名: N-(3-chloro-2H-indazol-5-yl)-6-(1,2,3,6-tetrahydropyridin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine
• CAS: 876343-27-0
• 化学式: C₁₈H₁₆ClN₇
• 分子量: 365.825
• InChiKey: AISCJLTXVLZXCN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  26
• 可旋转键数：
  3
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  94.3
• 氢给体数：
  4
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (3-chloro-1H-indazol-5-yl)-[6-(1,2,3,6-tetrahydropyridin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-amine 、 二碳酸二叔丁酯 在 N,N-二异丙基乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 2.0h， 生成 4-[4-(3-chloro-1H-indazol-5-ylamino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester
  参考文献：
  名称：

  [EN] ARYL-AMINO SUBSTITUTED PYRROLOPYRIMIDINE MULTI-KINASE INHIBITING COMPOUNDS
  [FR] COMPOSES A BASE DE PYRROLOPYRIMIDINE A SUBSTITUTION ARYLAMINE INHIBITEURS DE KINASES MULTIPLES

  摘要：

  公开号：

  WO2006017443A3
• 作为产物：
  描述：

  4-(4-chloro-7H-pyrrolo[2,3-d]pyrimidin-6-yl)-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester 、 3-氯-5-氨基-1H-吲唑 在 异丙醇 作用下， 生成 (3-chloro-1H-indazol-5-yl)-[6-(1,2,3,6-tetrahydropyridin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-amine
  参考文献：
  名称：

  [EN] ARYL-AMINO SUBSTITUTED PYRROLOPYRIMIDINE MULTI-KINASE INHIBITING COMPOUNDS
  [FR] COMPOSES A BASE DE PYRROLOPYRIMIDINE A SUBSTITUTION ARYLAMINE INHIBITEURS DE KINASES MULTIPLES

  摘要：

  公开号：

  WO2006017443A3

文献信息

• Aryl-amino substituted pyrrolopyrimidine multi-kinase inhibiting compounds
  申请人：Ahmed Saleh

  公开号：US20060211678A1

  公开（公告）日：2006-09-21

  Compounds represented by Formula (I): or stereoisomers or pharmaceutically acceptable salts thereof, are inhibitors of least two of the Abl, Aurora-A, Blk, c-Raf, cSRC, Src, PRK2, FGFR3, Flt3, Lck, Mek1, PDK-1, GSK3β, EGFR, p70S6K, BMX, SGK, CaMKII, Tie-2, IGF-1R, Ron, Ret, and KDR kinases in animals, including humans, for the treatment and/or prevention of various diseases and conditions such as cancer.

  化合物式(I)所代表的化合物，或其立体异构体或药学上可接受的盐，是动物，包括人类体内至少两种Abl，Aurora-A，Blk，c-Raf，cSRC，Src，PRK2，FGFR3，Flt3，Lck，Mek1，PDK-1，GSK3β，EGFR，p70S6K，BMX，SGK，CaMKII，Tie-2，IGF-1R，Ron，Ret和KDR激酶的抑制剂，用于治疗和/或预防各种疾病和病症，如癌症。
• Substituted pyrrolo[2.3-B]pyridines
  申请人：OSI Pharmaceuticals, Inc.

  公开号：US07465726B2

  公开（公告）日：2008-12-16

  Compounds represented by Formula (I): or stereoisomers or pharmaceutically acceptable salts thereof, are inhibitors of least two of the Abl, Aurora-A, Blk, c-Raf, cSRC, Src, PRK2, FGFR3, Flt3, Lck, Mek1, PDK-1, GSK3β, EGFR, p70S6K, BMX, SGK, CaMKII, Tie-2, IGF-1R, Ron, Ret, and KDR kinases in animals, including humans, for the treatment and/or prevention of various diseases and conditions such as cancer.

  公式（I）所代表的化合物，或其立体异构体或药学上可接受的盐，是动物，包括人类中至少两种Abl，Aurora-A，Blk，c-Raf，cSRC，Src，PRK2，FGFR3，Flt3，Lck，Mek1，PDK-1，GSK3β，EGFR，p70S6K，BMX，SGK，CaMKII，Tie-2，IGF-1R，Ron，Ret和KDR激酶的抑制剂，用于治疗和/或预防各种疾病和病况，如癌症。
• SUBSTITUTED INDAZOL-PYRROLOPYRIMIDINES USEFUL IN THE TREATMENT OF HYPERFOLIFERATIVE DISORDERS
  申请人：BAYER PHARMA AKTIENGESELLSCHAFT

  公开号：US20150218173A1

  公开（公告）日：2015-08-06

  The present invention relates to substituted indazol-pyrrolopyrimidine compounds of general formula I: in which R 1a , R 1b , R 1c , R 1d , R 2a are as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.

  本发明涉及通式I的取代的吲哚嘧啶-吡咯并嘧啶化合物：其中R1a，R1b，R1c，R1d，R2a如本文所述和定义，以及制备该化合物的方法，用于制备该化合物的中间化合物，包含该化合物的药物组合物和组合物，以及使用该化合物制造用于治疗或预防疾病的药物组合物，特别是用作唯一的活性成分或与其他活性成分组合使用，这些疾病特别是增生性和/或血管生成障碍。
• SUBSTITUTED INDAZOL-PYRROLOPYRIMIDINES USEFUL IN THE TREATMENT OF HYPERPROLIFERATIVE DISEASES
  申请人：BAYER PHARMA AKTIENGESELLSCHAFT

  公开号：US20150252047A1

  公开（公告）日：2015-09-10

  The present invention relates to substituted indazol-pyrrolopyrimidine compounds of general formula (I): in which R 1a , R 1b , R 1c , R 1d , R 2a and R 2b are as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.

  本发明涉及一般式（I）的取代吲唑-吡咯并嘧啶化合物，其中R1a、R1b、R1c、R1d、R2a和R2b如本文所述和定义，以制备该化合物的方法，用于制备该化合物的中间体化合物，包含该化合物的制药组合物和组合物，以及使用该化合物制造用于治疗或预防疾病，特别是增殖过度和/或血管生成障碍的药物组合物，作为唯一的活性成分或与其他活性成分结合使用。
• US7465726B2
  申请人：——

  公开号：US7465726B2

  公开（公告）日：2008-12-16